

#### OriGene Technologies, Inc.

9620 Medical Center Dr., Suite 200, Rockville, MD 20850 Phone: 1.888.267.4436 Fax: 301-340-9254 Email: techsupport@origene.com Web: www.origene.com

# **Product Information**

C-Peptide ELISA kit

Catalog Number: EA100869 Storage Temperature: 2 – 8°C

# Instruction for Use

# Intended Use

The C-peptide ELISA kit is intended for the quantitative determination of human C-peptide levels in human serum.

# Background

Human C-Peptide has a molecular mass of approximately 3000 daltons. C-Peptide has no metabolic function. However, since C-Peptide and insulin are secreted in equimolar amounts, the immunoassay of C-Peptide permits the quantitation of insulin secretion. This is the reason for the clinical interest of serum or plasma determinations of C- Peptide. Moreover, C-Peptide measurement has several advantages over immunoassays of insulin. The half-life of C- Peptide in the circulation is between two and five times longer than that of insulin. Therefore, C-Peptide levels are a more stable indicator of insulin secretion than the more rapidly changing levels of insulin. A very clear practical advantage of C-Peptide measurement arising from its relative metabolic inertness as compared to insulin is that C- Peptide levels in peripheral venous blood are about 5-6 times greater than insulin levels. Also, relative to an insulin assay, the C-Peptide assay's advantage is its ability to distinguish endogenous from injected insulin. C-Peptide has also been measured as an additional means for evaluating glucose tolerance and glibenclamide glucose tests. C- Peptide levels are in many ways a better measurement of endogenous insulin secretion than peripheral insulin levels. C-Peptide may be measured in either blood or urine. With improved sensitive C-Peptide immunoassays, it is now possible to measure C-Peptide values at extremely low levels. The clinical indications for C-Peptide measurement include diagnosis of insulinoma and differentiation from factitious hypoglycemia, follow-up of pancreatectomy, and evaluation of viability of islet cell transplants. Recently, these indications have been dramatically expanded to permit evaluation of insulin dependence in maturity onset diabetes mellitus

### **Principle of the Test**

The C-Peptide is a solid phase direct sandwich ELISA method. The samples and conjugate reagent (anti C-peptide biotin & HRP) are added to the wells coated with Streptavidin. C-peptide in the patient's serum binds to the matched pair Abs, forming a sandwich complex and simultaneously the complex is being immobilized on the plate through streptavidin-biotin interactions. Unbound proteins and HRP conjugate is washed off by wash buffer. Upon the addition of the substrate, the intensity of color is proportional to the concentration of C-peptide in the samples. A standard curve is prepared relating color intensity to the concentration of the C-Peptide.



#### Components

MATERIALS PROVIDED	96 Tests
1. Microwells coated with Streptavidin	12x8x1
2. Standards (1-6) 6 vials, lyophylized	Reconstitute with 1 ml DH2O
3. C-peptide Conjugate Reagent (ready to use)	12 ml
4. TMB Substrate (ready to use)	12 ml
5. Stop Solution (ready to use)	12 ml
6. Wash Solution 20x	25 ml

# Materials and Equipment Required but Not Provided

- 1. Distilled or deionized water
- 2. Precision pipettes
- 3. Disposable pipette tips
- 4. ELISA reader capable of reading absorbance at 450nm
- 5. Absorbance paper or paper towel
- 6. Graph paper

# Disclaimer

This product is for research use only and not intended for diagnostic procedures.

# **Specimen Collection Handling**

- 1. Collect blood specimens and separate the serum immediately.
- 2. Specimens may be stored refrigerated at (2-8 °C) for 2 days. If storage time exceeds 2 days, store frozen at -20 °C for up to one month.
- 3. Avoid multiple freeze-thaw cycles.
- 4. Prior to assay, frozen sera should be completely thawed and mixed well.
- 5. Do not use grossly hemolyzed or lipemic specimens.

### **Reagent Preparation**

 Standards: Reconstitute the lyophilized standards with 1 ml distilled water. Allow them to remain undisturbed until completely dissolved, and then mix well by gentle inversion. The reconstituted standards are stable for 24 hours when stored sealed at 2-8 °C. To assure maximum

stability of the reconstituted standards, aliquot the standards and store at -20 °C. Do not freeze-thaw more than once.

2. **Prepare 1X Wash buffer**: Add the Wash Buffer (20x, 25 ml) to 475 ml of distilled or de-ionized water. Store at room temperature (20-25°C).

# **Assay Procedure**

- Before proceeding with the assay, bring all reagents, serum references and controls to room temperature (20-25°C). Gently mix all reagents before use
- The components in this kit are intended for use as an integral unit. The components of different lots should not be mixed
- It is recommended that standards, control, and serum samples be run in duplicate
- Do not use sodium azide as preservative. Sodium azide inhibits HRP enzyme activities



- 1. Format the microplate wells for each reference, control, and patient specimen to be assayed in duplicate. Replace any unused microwell strips back into the aluminum bag, seal, and store at 2-8°C.
- 2. Pipette 50 µl of the appropriate standard, control, or specimen into the assigned well.
- 3. Pipette 100 µl C peptide conjugate reagent into each well.
- 4. Cover the plate and incubate for 60 minutes at room temperature (20-25 °C).
- 5. Remove liquid from all wells. Wash wells three times with 300 µl of 1x wash buffer. Blot on absorbent paper towels.
- 6. Add 100 µl of TMB substrate to all wells.
- 7. Incubate for 15 minutes at room temperature.
- 8. Add 50 µl of stop solution to all wells. Shake the plate gently to mix the solution.
- 9. Read absorbance on ELISA Reader at 450 nm within 15 minutes after adding the stopping solution.

### Calculation of Results

The standard curve is constructed as follows:

- 1. Check C-Peptide standard value on each standard vial. This value might vary from lot to lot. Make sure you check the value on every kit. See example of the standard attached.
- 2. To construct the standard curve, plot the OD (Optical Density) for each Total C-Peptide standard point (Yaxis) versus the Total C-Peptide standard concentrations (X-axis) on a linear graph paper. Draw the best curve through the points.
- 3. Read the concentration (ng/ml) for controls and each unknown sample from the curve. Record the value for each control or unknown sample
- 4. Any values obtained for diluted samples must be further converted by applying the appropriate dilution factor in the calculations.

### **Example of Standard Curve**

The following data is for demonstration only and cannot be used in place of data generations at the time of assay.

Standard	Conc.ng/mL	OD450
Std 1	0	0.01
Std 2	0.15	0.03
Std 3	0.75	0.15
Std 4	2.0	0.4
Std 5	6	1.29
Std 6	10.0	2.26

#### References

- 1. Ashby, J. and Frier, B.: Circulating C-Peptide: Measurement and Clinical Applications. Annals of Clinical Biochemistry. 18:125, 1981.
- 2. Beischer, W.: Proinsulin and C-Peptide in Humans. Hormones in Normal and Abnormal Human Tissues. Volume 3K, Fotherby and Pal, S., ed. (Berlin: Walter DeGruyter). pp. 1-43, 1983
- 3. Beyer, J., Krause V., Cordes V.: C-Peptide: Its Biogenesis, Structure, Determination and Clinical Significance. Giornale Italiano di Chimica Clinica 4 Supp. 9:22, 1979



#### OriGene Technologies, Inc.

- 4. Bonger, A. and Garcia-Webb, P.: C-Peptide Measurement: Methods and Clinical Utility. CRC Critical Reviews in Clinical Laboratory Sciences. 19:297, 1984.
- Blix, P. Boddie-Wills, C., Landau, R., Rochman, H. Rubenstein, A.: Urinary C-Peptide: An Indicator of Beta-Cell Secretion under Different Metabolic Conditions. Journal of Clinical Endocrinology and Metabolism. 54:574, 1982.
- 6. Rendell, M.: C-Peptide Levels as a Criterion in Treatment of Maturity-Onset Diabetes. Journal of Clinical Endocrinology and Metabolism. 57 (6): 1198, 1983
- 7. Horwitz, D., et al.: Proinsulin, Insulin and C-Peptide concentrations in Human Portal and Peripheral Blood. Journal of Clinical Investigation. 55:1278, 1975

Version 4, last updated December 6th, 2021